19642-68-3

Basic information

• Product Name: 5-broMopyridine-2-sulfonaMide
• Synonyms: 5-broMopyridine-2-sulfonaMide
• CAS NO: 19642-68-3
• Molecular Formula: C₅H₅BrN₂O₂S
• Molecular Weight: 237.0744
• EINECS: -0
• Mol File: 19642-68-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-broMopyridine-2-sulfonaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-broMopyridine-2-sulfonaMide(19642-68-3)
• EPA Substance Registry System: 5-broMopyridine-2-sulfonaMide(19642-68-3)

Safety Data

• Hazardous Substances Data: 19642-68-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
5-bromopyridine-2-sulfonamide is used as a building block for the synthesis of various pharmaceutical and agrochemical compounds. Its diverse pharmacological activities, including antimicrobial, antiviral, and antitumor properties, make it a valuable component in the development of new drugs and agrochemicals.
Used in Medicinal Chemistry and Drug Discovery:
5-bromopyridine-2-sulfonamide is utilized as a key intermediate in the synthesis of compounds with potential therapeutic applications. Its unique chemical structure and properties contribute to the discovery of new drugs with improved efficacy and safety profiles.
Used in Coordination Chemistry and Catalysis:
5-bromopyridine-2-sulfonamide has been studied for its potential use as a ligand in coordination chemistry and catalysis. Its ability to form stable complexes with metal ions and its potential catalytic properties make it a promising candidate for applications in these fields.

Upstream product

• 874959-69-0 2-(benzylsulfanyl)-5-bromopyridine 
• 53939-30-3 5-bromo-2-chloropyridine 
• 874959-68-9 5-bromopyridine-2-sulfonyl chloride 

Downstream Products

• 1272355-61-9 5-(5-phenyl-4-((pyridin-2-ylmethyl)amino)quinazolin-2-yl)pyridine-2-sulfonamide 

Relevant articles and documents

Selective IKur Inhibitors for the Potential Treatment of Atrial Fibrillation: Optimization of the Phenyl Quinazoline Series Leading to Clinical Candidate 5-[5-Phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide

We have recently disclosed 5-phenyl-N-(pyridin-2-ylmethyl)-2-(pyrimidin-5-yl)quinazolin-4-amine 1 as a potent IKur current blocker with selectivity versus hERG, Na and Ca channels, and an acceptable preclinical PK profile. Upon further characterization in vivo, compound 1 demonstrated an unacceptable level of brain penetration. In an effort to reduce the level of brain penetration while maintaining the overall profile, SAR was developed at the C2′ position for a series of close analogues by employing hydrogen bond donors. As a result, 5-[5-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine-3-sulfonamide (25) was identified as the lead compound in this series. Compound 25 showed robust effects in rabbit and canine pharmacodynamic models and an acceptable cross-species pharmacokinetic profile and was advanced as the clinical candidate. Further optimization of 25 to mitigate pH-dependent absorption resulted in identification of the corresponding phosphoramide prodrug (29) with an improved solubility and pharmacokinetic profile.

3-PHOSPHOGLYCERATE DEHYDROGENASE INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

NOVEL 3-(INDOL-3-YL)-PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE

The present invention relates to compound of Formula I or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.